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Abstract: ABSTRACT Background Arrhythmogenic right ventricular Cardiomyopathy/Dysplasia (ARVC/D) is a genetic disease predominantly caused by desmosomal gene mutations that account for only ~50% of cases. RYR2 gene mutations usually cause Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) but have been associated with peculiar phenotype named ARVC2. Objectives We aim to determine the prevalence and phenotype associated with RYR2 mutations in a large ARVC/D population. Methods We analyzed the whole RYR2 coding sequence by Sanger sequencing in 64 ARVC/D probands without desmosomal gene mutations.
Results
We have identified six rare missense variants p.P1583S, p.A2213S, p.G2367R, p.Y2932H, p.V3219M and p.L4670V. It corresponds to a prevalence of 9% of rare RYR2 variants in ARVC/D population (6 probands/64) that is significantly higher than the estimated rate of rare RYR2 variants in control (Fisher test, p=0.03) . Phenotypes associated with RYR2 variants were similar to desmosome-related ARVC/D, associating typical ECG abnormalities at rest, frequent monomorphic ventricular tachycardia, right ventricular dilatation, wall motion abnormalities and fibro-fatty replacement when histopathological examination was available.
Conclusion
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The questions raised were adequately addressed. We aim to determine the prevalence and phenotype associated with RYR2 mutations in a large 8 ARVC/D population. 9
Methods
10
We analyzed the whole RYR2 coding sequence by Sanger sequencing in 64 ARVC/D 11 probands without desmosomal gene mutations.
13
Results
14
We have identified six rare missense variants p.P1583S, p.A2213S, p.G2367R, 15 p.Y2932H, p.V3219M and p.L4670V. It corresponds to a prevalence of 9% of rare RYR2 16 variants in ARVC/D population (6 probands/64) that is significantly higher than the estimated 17 rate of rare RYR2 variants in control (Fisher test, p=0.03). Phenotypes associated with RYR2 18 variants were similar to desmosome-related ARVC/D, associating typical ECG abnormalities 19 at rest, frequent monomorphic ventricular tachycardia, right ventricular dilatation, wall 20 motion abnormalities and fibro-fatty replacement when histopathological examination was Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) is a rare cardiac 2 muscle disorder characterised by progressive fibro-fatty replacement of the myocardium. The 3 right ventricle is predominantly affected but left ventricular involvement is also present in 4 more than half of the cases 1 . These structural alterations can lead to ventricular arrhythmias 5 and heart failure. ARVC/D is a frequent cause of sudden death in young people and athletes.
6
The diagnosis of ARVC/D is currently based on the presence of major and minor standardised In this study, we aimed to determine the prevalence of RYR2 mutations in a large cohort of 64 Clinical data are summarised in the tables 1 and S1. Pedigrees are presented in figure 1.
2 Family A. 3 The proband was a man presenting with aborted sudden cardiac death during intense effort, 4 with ventricular fibrillation. Resting ECG showed in V1 an atypical conduction defect (figure or isoproterenol test did not induced significant arrhythmia in the proband and his father. 
23
RYR2 is reported to be a relatively polymorphic gene by Jabbari et al 26 . We decided therefore 24 to analyse whether the prevalence of RYR2 variant in our cohort was higher or not than in the 25 general population. We estimated the prevalence of the genetic background noise of RYR2 1 variants in the general population using the data from the Exome Variant Server. We 2 considered as a rare RYR2 variant a variant observed at maximum 5 times in EVS, which is a 3 conservative approach. We observed that a rare RYR2 variant was identified in 215/5818 4 subjects in EVS (supplementary table 2). It corresponded to a rate of rare RYR2 variants of 5 4% (215/5818) in EVS which was significantly lower to the 9% (6/64) observed in our cohort 6 (Fisher test, p=0.0322). "genetic background noise" of 4% in RYR2, we found a significantly higher frequency of 16 RYR2 variants in our ARVC/D cohort.
17
In the absence of functional studies, it remains difficult to classify any missense mutation as 18 benign or pathogenic. Therefore, interpretation of our results was performed with 19 considerable caution. We postulate that some of the new variants identified in our study are 20 deleterious, either as a monogenic dominant mutation or through a modifier effect, while we 21 cannot exclude the hypothesis that some variants may be very rare benign polymorphisms.
22
The two variants, p.P1583S and p.L4670V were considered as highly probably pathogenic 23 based on the conservation of the amino acid concerned, the absence of a large control 24 population and the damaging effect predicted in silico. The familial studies showed that the 25 variants segregate with the phenotype but with reduced penetrance. The pathogenic effect of 1 p.A2213S, p.G2367R, p.Y2932H, p.V3219M was more difficult to ascertain. In silico 2 analyses suggest that these variants are possible benign polymorphisms or modifying variants 3 rather than direct disease-causing mutations.
4
Noticeably, we identified the presence of the two RYR2 SNPs (p.G1885E and p.G1886S) in 5 a compound heterozygous manner in one additional proband, which were previously reported 6 to be associated with ARVC/D (data not shown) 24 . However, we also identified this 7 association in a healthy control subject supporting a possible modifier effect of these variants 8 rather than a causal role.
9
The RYR2 mutations identified so far in ARVC/D were located in the cytoplasmic region of 10 the channel 11, 22, 23 . Similarly, all the genetic variants we identified were also located in the 11 cytoplasmic part of the protein, except the p.L4670V variant, which is located into the 12 transmembrane domain, a hot spot of RYR2 mutations associated with CPVT phenotypes 29 . 13 We therefore believe that the molecular analyse of RYR2 in ARVC/D requires the screening 14 of the entire coding region of the gene.
15
Phenotype/genotype analysis 16 Until now, only few studies reported RYR2 mutations associated with ARVC/D 11,22,23 17 (ARVC2 locus). In those families, the phenotype linked to RYR2 mutations appeared different 18 from desmosome-related ARVC/D and presented overlapped characteristics with CPVT 11 .
19
Interestingly, in the present study, the phenotype associated with RYR2 variants is similar to A limit of this study is the absence of definitive demonstration for the pathogenicity of the 1 RYR2 variants, because of inconclusive segregation analyses and no available functional 2 studies. However, one of the variants was previously reported to cause a gain of function 27,28 .
3 Moreover, the small size of families is quite usual in ARVC/D because of reduced penetrance 4 and therefore few affected relatives in a family. In addition we performed a careful and 5 conservative interpretation of the variants.
6
Another limit concerns the comparison of the rate of RYR2 variants in our cohort and in EVS 7 cohort while two different methods of sequencing were used, which performance may differ 8 (error rate, coverage). However, their efficiency in term of error rate seems to be similar 31 and 9 the coverage of the coding sequence of RYR2 in EVS was excellent (99.9%). We are therefore 10 confident with the true difference of RYR2 variants in patients and controls, although the 11 analysis of a larger cohort of patients with NGS could strengthen our findings.
12
At last, the ARVC/D probands were selected according to the 1994 Task Force Criteria as this 13 cohort was prospectively recruited before the publication of the revised TFC. CONCLUSION 16 We performed the first systematic screening of the whole RYR2 gene in a well clinically 17 characterized ARVC/D cohort, after the exclusion of patients with pathological mutations in 18 five desmosomal genes, and identified putative RYR2 mutations in 9% of ARVC/D probands.
19
Furthermore, we observed that RYR2 variants were associated with ARVC/D not overlapping factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. To our knowledge, we report here the first systematic screening of the whole RYR2 gene in a 2 large ARVC/D cohort without mutation in desmosomal genes. We identified six rare RYR2 3 missense variants predominantly associated with a conventional phenotype of ARVC/D.
4
Using the data from the Exome Variant Server database, we estimated the prevalence of rare 5 RYR2 variants to 4% in the general population, which was significantly lower to the 9% 6 observed in our cohort (Fisher test, p=0.0322). The results support the role of RYR2 gene in ACEi: angiotensin conversion enzyme inhibitor; AF: atrial fibrillation; BB: beta-blockers; Echo: echocardiography; EF: ejection fraction; FAC: fractional area change; Heart Tx: heart transplantation; ICD: implantable cardiac defibrillator;
LGE: presence of late-gadolinium enhancement; LV: left ventricle; NA: non-available data; Pb: proband (all fulfilled 1994 diagnostic criteria available at enrolment); PSAX: para-sternal short axis; R: relative; RV: right ventricle; RBBB: right bundle branch block; SCD: sudden cardiac death; SAECG: signal average ECG; RVOT: right ventricle outflow tract; TWI: T-wave inversion; WMA: wall motion abnormalities; *: min or criteria according to the 2010 Task Force Diagnosis Criteria (TFDC); **: major criteria; †: fibrofatty replacement. 
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